Pharmacokinetics, Safety and Tolerability of Different Formulations and Dose Strengths of Quarterly Risperidone (QUAR) in Patients With Schizophrenia - Trial NCT06276361
Access comprehensive clinical trial information for NCT06276361 through Pure Global AI's free database. This Phase 1 trial is sponsored by Rovi Pharmaceuticals Laboratories and is currently Recruiting. The study focuses on Schizophrenia. Target enrollment is 100 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Rovi Pharmaceuticals Laboratories
Timeline & Enrollment
Phase 1
Sep 26, 2023
May 01, 2026
Primary Outcome
ฮปz,t1/2,Tmax,Cmax,Cmin,Clast,AUC0-t,AUCinf,AUCextrap,Vd/F,Cl/F
Summary
This is a single ascending dose phase 1 study to evaluate the pharmacokinetics (PK), safety,
 and tolerability of a single intramuscular (IM) injection of quarterly Risperidone (QUAR) for
 different formulations and dose strengths in participants with schizophrenia.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06276361
Non-Device Trial